4.7 Article

Combinatorial Intracellular Delivery Screening of Anticancer Drugs

期刊

MOLECULAR PHARMACEUTICS
卷 17, 期 12, 页码 4709-4714

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acs.molpharmaceut.0c00791

关键词

drug screening; combination therapy; polymeric nanoparticles; drug solubilization; intracellular drug delivery; synergy analysis

资金

  1. ERC [MEViC 278793, CheSSTaG 769798]
  2. EPSRC/BTG Healthcare Partnership [EP/I00 1697/1]
  3. EPSRC Established Career Fellowship [EP/N026322/1]
  4. Children with Cancer UK [16-227]
  5. EPSRC/SomaNautix Healthcare Partnership [EP/R024723/1]
  6. EPSRC [EP/R024723/1, EP/N026322/1, EP/I001697/1] Funding Source: UKRI

向作者/读者索取更多资源

Conventional drug solubilization strategies limit the understanding of the full potential of poorly water-soluble drugs during drug screening. Here, we propose a screening approach in which poorly water-soluble drugs are entrapped in poly(2-(methacryloyloxyethyl phosphorylcholine)-poly(2-(diisopropylaminoethyl methacryate) (PMPC-PDPA) polymersomes (POs) to enhance drug solubility and facilitate intracellular delivery. By using a human pediatric glioma cell model, we demonstrated that PMPC-PDPA POs mediated intracellular delivery of cytotoxic and epigenetic drugs by receptor-mediated endocytosis. Additionally, when delivered in combination, drug-loaded PMPC-PDPA POs triggered both an enhanced drug efficacy and synergy compared to that of a conventional combinatorial screening. Hence, our comprehensive synergy analysis illustrates that our screening methodology, in which PMPC-PDPA POs are used for intracellular codelivery of drugs, allows us to identify potent synergistic profiles of anticancer drugs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据